entasis therapeutics stock news
Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference, Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update, Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference, Entasis Therapeutics Appoints Dr. Howard Mayer to Board of Directors, Entasis Therapeutics CEO: 'Our Antibiotics Work Differently', Entasis Therapeutics Appoints David Meek as Chairman of the Board, Entasis Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference, Entasis Therapeutics Announces Initial ETX0282 Phase 1 Results, Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019, Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections, Entasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update, Entasis Therapeutics Strengthens Leadership Team with Appointment of Eric Kimble as Chief Commercial Officer, Entasis Therapeutics Announces the Appointment of Elizabeth Keiley as General Counsel, Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019, Entasis launches late-stage study of antibiotic combo, Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections, Entasis Therapeutics Holdings Inc. (ETTX) Moves to Buy: Rationale Behind the Upgrade, Entasis Therapeutics to Present at H.C. Wainwright & Co. Earnings for Entasis Therapeutics are expected to grow in the coming year, from ($2.49) to ($1.33) per share. Entasis Therapeutics Awarded Contract from National Institutes of Health. Global Life Sciences Conference in London, Entasis Therapeutics Reports Full Year 2018 Financial Results and Provides Business Update, Receive Analysts' Upgrades and Downgrades Daily. NASDAQ 0.00%. The Average True Range (ATR) for Entasis Therapeutics Holdings Inc. is set at 0.08 The Price to Book ratio for the last quarter was 0.88. Find the latest Entasis Therapeutics Holdings I (ETTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Dow Futures +0.12% +37.00. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Fundamental company data provided by Zacks Investment Research. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Should You Sell Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) For This Reason? Our pipeline consists of clinical and pre-clinical pathogen-targeted small-molecule antibacterials for the treatment of multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumanii, carbapenem-resistant Enterobacteriaceae, and … 18, 2020 at 9:34 a.m. The company’s stock price has collected 23.76% of gains in the last five trading sessions. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. ETTX Stock Summary. View our full suite of financial calendars and market data tables, all for free. Real-time trade and investing ideas on Entasis Therapeutics Ltd ETTX from the largest community of traders and investors. Get daily stock ideas top-performing Wall Street analysts. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba... WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba... WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of ... Wall Street sell-side analysts are positive about Ekso Bionics Holdings Inc (NASDAQ:EKSO) and Entasis Therapeutics Holdings Inc (NASDAQ:ETTX), even though their holdings have lost more than 59% over the... WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of... CEO Dr. Manos Perros participated in Industry Panel today CEO Dr. Manos Perros participated in Industry Panel today. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. GENEVA and WALTHAM, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organization developing new treatments for drug resis... WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antib... Entasis Therapeutics Holdings Inc. (ETTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set. Are Institutions Heavily Invested In Entasis Therapeutics Holdings Inc.'s (NASDAQ:ETTX) Shares? Entasis Therapeutics Holdings Inc. stock price ended on $2.92 on Tuesday after losing 3.95% (Updated on March 16, 2021) Hold candidate since 2021-03-15 Loss -3.95% PDF . Yahoo | July 6, 2020. Press Release reported on 11/17/20 that Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. WALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba... Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Subscribe. Entasis Stock News module provides quick insight into current market opportunities from investing in Entasis Therapeutics Holdings. Entasis Therapeutics Holdings Inc stock is down -63.28% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives ETTX stock … Jaffetilchin Investment Partners LLC acquired a new position in shares of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. See what's happening in the market right now with MarketBeat's real-time news feed. Entasis Therapeutics (ETTX) stock price, charts, trades & the US's most popular discussion forums. Find the latest news headlines from Entasis Therapeutics Holdings Inc. Common Stock (ETTX) at Nasdaq.com. The analyst firm set a price target for 5.00 expecting ETTX to … According to 7 analysts, the average rating for ETTX stock is "Buy." Cancel. Get the latest Entasis Therapeutics Holdings I (ETTX) stock news and headlines to help you in your trading and investing decisions. ETTX: Get the latest Entasis Therapeutics stock price and detailed information including ETTX news, historical charts and realtime prices. Sign Up. Markets Insider. Entasis Therapeutics News: This is the News-site for the company Entasis Therapeutics on Markets Insider. May. Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. quote : historical data and live quotes, charts, news, analyses, trading signals, calendar, informations and community tools Log In. A high-level overview of Entasis Therapeutics Holdings Inc. (ETTX) stock. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. View which stocks have been most impacted by COVID-19. Markets Stocks Indices Commodities Cryptocurrencies Currencies ETFs News Economic; Earnings; U.S. markets closed. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Entasis Therapeutics Ltd 2.92 0.12 (3.95%) Watch. Losses were -$43.85 million, 4.17% more than in 2018. Please log in to your account or sign up in order to add this asset to your watchlist. What price target have analysts set for ETTX? © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The fund acquired 11,000 shares of the company’s stock, valued at approximately $27,000. ENTASIS THERAPEUTICS HOLDINGS INC. : News, information and stories for ENTASIS THERAPEUTICS HOLDINGS INC. | Nasdaq: ETTX | Nasdaq Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Entasis Therapeutics against related stocks people have also bought. Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set. The Entasis Therapeutics Holdings Inc. stock price fell by -3.95% on the last day (Tuesday, 16th Mar 2021) from $3.04 to $2.92.During the day the stock … Many technical investors use Entasis Therapeutics stock news … Company profile page for Entasis Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information ETTX Stock Performance Analysis: Entasis Therapeutics … ENTASIS THERAPEUTICS HLD. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference, We Think Entasis Therapeutics Holdings (NASDAQ:ETTX) Needs To Drive Business Growth Carefully, Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium, Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update, Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences, Entasis Therapeutics secures equity raise of $25M, Entasis Therapeutics Reports Second Quarter 2020 Financial Results and Business Update, Entasis Therapeutics to Participate in Upcoming Healthcare Conferences, Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%, Entasis Therapeutics nabs NIH contract for $3M, Entasis Therapeutics to Participate in the BMO 2020 Prescriptions for Success Healthcare Conference, Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva, Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva, Entasis Therapeutics up 181% amid Covid-19 frenzy, Earnings Release: Here's Why Analysts Cut Their Entasis Therapeutics Holdings Inc. Price Target To US$14.50, Entasis Therapeutics EPS misses by $0.40, misses on revenue, Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update, Introducing Entasis Therapeutics Holdings (NASDAQ:ETTX), The Stock That Dropped 16% In The Last Year, Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update, Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer, Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference, Entasis Therapeutics Announces Multiple Presentations at ID Week 2019, GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea. 31,463.00. Use historical and current headlines to determine the investment entry and exit points. Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4% Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. Jan 26, 2021 Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference Many technical investors use Entasis Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly. ET on GuruFocus.com Entasis Therapeutics Holdings Ltd. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. View the latest Entasis Therapeutics Holdings Ltd. (ETTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Start Your Risk-Free Trial Subscription Here, 3 Homebuilder Stocks Making Constructive Moves, Whatever You Believe About Sundial Growers, You Could Be Right, SunPower Stock is a Best of Breed Solar Play, The Exodus Movement, Inc Ushers In A New Age Of IPO, Ford Stock Gains Big on Upgrade at Barclays, Nike Slips On Earnings, Traction Forecast For Later In The Year, FedEx Breaks Out On Q3 Earnings And Outlook, Cintas Falls On Great Results, Growth Is Back On The Table, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. Looking for new stock ideas? © American Consumer News, LLC dba MarketBeat® 2010-2021. Entasis Therapeutics Holdings Inc. (ETTX) shares on Friday’s trading session, dropped -1.17 percent to see the stock exchange hands at $3.39 per unit. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. WALTHAM, Mass., July 06, 2020 -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel. Get the latest Entasis Therapeutics Holdings I (ETTX) stock news and headlines to help you in your trading and investment decisions. Export data to Excel for your own analysis. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4% finance.yahoo.com - July 13 at 12:52 PM: Entasis Therapeutics nabs NIH contract for $3M seekingalpha.com - July 6 at 1:09 PM: Entasis Therapeutics to Participate in the BMO 2020 Prescriptions for Success Healthcare Conference finance.yahoo.com - June 18 … In 2019, ETTX's revenue was $7.00 million, an increase of 40.00% compared to the previous year's $5.00 million. Trending now. GlobeNewsWire - 8 months ago Entasis Therapeutics Awarded Contract from … Several other hedge funds and other institutional investors have also Learn more. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. All rights reserved. Our Accessibility Statement S&P 500 0.00%. DOW 0.00%. Detailed financial statements for Entasis Therapeutics stock (ETTX), including the income statement, balance sheet, and cash flow statement. Entasis Therapeutics Ltd PRIVATE Updated Mar 16, 2021 9:07 PM. Use historical and current headlines to determine the investment entry and exit points. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Entasis Therapeutics (ETTX) stock price, charts, trades & the US's most popular discussion forums. Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. Want to see which stocks are moving? Learn more. Find real-time ETTX - Entasis Therapeutics Holdings Inc stock quotes, company profile, news and forecasts from CNN Business. Do Not Sell My Information. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. Benzinga 56d 40 Stocks Moving in Wednesday's Pre … Since then, ETTX stock has decreased by 24.9% and is now trading at $3.10. Stock analysis for Entasis Therapeutics Holdings Inc (ETTX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Identify stocks that meet your criteria using seven unique stock screeners. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II... [Read more...]. Rooms Shows Rankings Earnings Calendar Shop.